IRADIMED CORPORATION — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This is an annual filing; it does not provide a standalone fourth-quarter results summary.
Business context
IRADIMED develops, manufactures, and sells MRI-compatible medical devices, principally its MRidium IV infusion pump and 3880 patient vital signs monitor, along with accessories, disposables, service, and extended warranties. It also began selling its FMD1 ferromagnetic detection system in 2022. Sales are primarily to hospitals and acute care facilities; the U.S. direct sales force serves domestic customers, while distributors serve international markets.
Financial performance and liquidity
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | $53.3 million | $41.8 million |
| Gross profit / margin | $41.3 million / 77.5% | $32.0 million / 76.6% |
| Operating income / margin | $15.6 million / 29.3% | $9.8 million / 23.5% |
| Net income | $12.8 million | $9.3 million |
| Diluted EPS | $1.02 | $0.74 |
| Cash from operations | $10.0 million | $11.3 million |
- Revenue rose 27.5%. U.S. revenue increased 31.0% to $43.9 million; international revenue rose 13.3% to $9.4 million. The U.S. accounted for 82.4% of revenue.
- Device revenue increased 34.7% to $36.5 million. Patient-monitor revenue grew 57.2% to $21.7 million, while infusion-pump revenue increased 9.0% to $14.5 million. FMD revenue was $0.3 million.
- Operating expenses rose to $25.7 million from $22.2 million, but declined as a share of revenue to 48.2% from 53.2%. Higher selling prices, volume, and overhead absorption supported gross margin; inflation raised raw-material costs.
- Cash and investments totaled $57.9 million at year-end, versus $62.5 million in 2021. Working capital was $68.9 million, compared with $69.4 million; stockholders’ equity was $73.7 million.
- Accounts receivable rose to $13.3 million from $5.1 million, and inventory to $5.4 million from $4.3 million. The filing attributes lower operating cash flow partly to receivables and accrued payroll movements.
- Cash used in investing activities was $1.4 million; cash used in financing was $12.7 million, principally reflecting a $12.6 million dividend. No interest-bearing borrowings are identified in the presented balance sheet; operating lease liabilities totaled $2.2 million.
Material changes, outlook, and risks
- Management said existing cash, investments, operating cash flow, and available financing should cover projected requirements for at least 12 months after issuance of the financial statements. The filing provides no quantified 2023 revenue or earnings guidance.
- Management cited lingering pandemic-related effects and longer-than-historical sales cycles, while pursuing U.S. market expansion, greater use in critical-care departments, international distributor growth, and new products.
- In February 2023, the company paid a $1.05-per-share special dividend totaling $13.2 million and purchased approximately 26.5 acres in Florida for $6.2 million as a future facility site. These are subsequent events, not 2022 operating results.
- Key exposures include reliance on a limited product portfolio, FDA and other regulatory requirements, potential product quality or recall issues, and single-source components. The MRI pump’s ultrasonic motor supplier agreement runs through February 25, 2024.
- EU market access requires continued compliance with the Medical Device Regulation; the company reported its CE certificates remained valid through May 2024. The company also operates from a Florida facility leased from an entity affiliated with CEO Roger Susi; it expects the planned facility to reduce this related-party exposure over time.
- Other notable risks include customer capital-spending constraints, distributor dependence abroad, supply-chain disruption, competition in patient monitors, and the influence of CEO Roger Susi, who beneficially owns approximately 43% of outstanding shares. The company reported $8.0 million in purchase orders outstanding at year-end.
- The 2022 effective tax rate was 20.7%, versus 5.2% in 2021, primarily because unusually large 2021 tax benefits from equity-award exercises and vesting did not recur to the same extent. New U.S. research-cost amortization rules increased deferred tax assets and cash tax liabilities by approximately $0.5 million.
Important facts for investors to verify
- Whether the sharp increase in accounts receivable converts to cash, and how customer payment timing affects operating cash flow.
- Whether growth in the 3880 monitor and newer FMD product can continue, and whether device sales support recurring disposable and service revenue.
- Supplier continuity and renewal or replacement plans for the sole-source pump motor agreement expiring in February 2024.
- Regulatory renewal and compliance milestones, including EU certification beyond May 2024, and any FDA developments affecting marketed products.
- Capital requirements and execution risks for the planned facility after the $6.2 million land purchase, alongside dividends and other shareholder returns.
- Related-party lease terms and transition plans; the filing reports management assessed disclosure controls and internal control over financial reporting as effective, while the auditor did not express an opinion on internal-control effectiveness.